01/26/23 7:00 AMNasdaq : TGTX TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple SclerosisTG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and activeRHEA-AIvery positive
01/06/23 7:30 AMNasdaq : TGTX conferencesTG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceTG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan HealthcareRHEA-AIneutral
12/28/22 1:48 PMNasdaq : TGTX fda approvalTG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion twice-a-year following the starting dose U.S. Commercial launch expected Q1 2023 Company to host conference call on Thursday,RHEA-AIvery positive
11/10/22 7:30 AMNasdaq : TGTX earningsTG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial ResultsTG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2022 and recent company developments, along with a business outlookRHEA-AIneutral
11/08/22 7:30 AMNasdaq : TGTX conferencesearningsTG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business UpdateTG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Thursday, November 10, 2022 at 8:30 AM ET to discuss results for the third quarter of 2022.RHEA-AIneutral
10/26/22 7:30 AMNasdaq : TGTX clinical trialTG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple SclerosisTG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), presented at the 2022RHEA-AIneutral
10/13/22 7:30 AMNasdaq : TGTX clinical trialTG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple SclerosisTG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2022RHEA-AIneutral
09/09/22 7:30 AMNasdaq : TGTX conferencesTG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceTG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate virtuallyRHEA-AIneutral
09/07/22 1:15 PMNYSE, Nasdaq : KSS, AZRE, TGTX LAWSUITS FILED AGAINST TGTX, AZRE and KSS - Jakubowitz Law Pursues Shareholders ClaimsJakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested inRHEA-AInegative
08/25/22 7:30 AMNasdaq : TGTX clinical trialTG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of MedicineUblituximab is an investigational targeted B-cell therapy that shows superior efficacy when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis ULTIMATE I and II demonstrated significant reductions in risk of relapses, as well as reduction of active or new brainRHEA-AIneutral